Strengths of our study include the large population of people with type 2 diabetes on insulin therapies included, and the fact that the NDR, SPDR and NPR have greater than 90% coverage of all adults with diabetes in Sweden. The gene discussed is INS; the disease is type 2 diabetes mellitus.